Cargando…

Ceftriaxone resistance and adequacy of initial antibiotic therapy in community onset bacterial pneumonia

Much remains unknown about the impact of initial antibiotic adequacy on mortality in community onset bacterial pneumonia (COBP). Therefore, we performed a study to determine how the adequacy of initial antibiotic therapy affects in-hospital mortality for patients with COBP. We carried out a retrospe...

Descripción completa

Detalles Bibliográficos
Autores principales: Van Besien, Richard F., Hampton, Nicholas, Micek, Scott T., Kollef, Marin H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9276381/
https://www.ncbi.nlm.nih.gov/pubmed/35608417
http://dx.doi.org/10.1097/MD.0000000000029159
_version_ 1784745712584491008
author Van Besien, Richard F.
Hampton, Nicholas
Micek, Scott T.
Kollef, Marin H.
author_facet Van Besien, Richard F.
Hampton, Nicholas
Micek, Scott T.
Kollef, Marin H.
author_sort Van Besien, Richard F.
collection PubMed
description Much remains unknown about the impact of initial antibiotic adequacy on mortality in community onset bacterial pneumonia (COBP). Therefore, we performed a study to determine how the adequacy of initial antibiotic therapy affects in-hospital mortality for patients with COBP. We carried out a retrospective cohort study among the 11 BJC Healthcare community and academic hospitals in Missouri and Illinois. The electronic medical records for BJC Healthcare were queried to obtain a set of patient admissions with culture positive (respiratory or blood) COBP admitted from January 1, 2016 through December 31, 2019. Patients with COBP required an International Classification of Diseases (ICD)-10 diagnostic code for pneumonia, admission to the hospital through an emergency department, a chest radiograph with an infiltrate, an abnormal white blood cell count or temperature, an order for 1 or more new antibiotics, and a positive respiratory or blood culture. Antibiotic selection was deemed adequate if the patient had organisms susceptible to at least one of the antibiotics received according to in vitro testing using standard laboratory breakpoints. Among 36,645 screened pneumonia admissions, 1843 met criteria for culture positive COBP. Eight hundred nineteen (44.4%) had ceftriaxone-resistant (CTX-R) organisms and 1024 had ceftriaxone-sensitive (CTX-S) organisms. The most common CTX-R pathogens were methicillin resistant Staphylococcus aureus (46.9%), Pseudomonas species (38.4%), and Escherichia coli (4.5%). On the day of admission 71% of all patients were given adequate antibiotic treatment (62.2% of CTX-R and 77.9% of CTX-S). Unnecessarily broad initial treatment was administered to 57.1% of CTX-S patients. In a logistic regression model accounting for comorbidities and severity of illness, inadequate therapy on the day of admission was associated with higher in-hospital mortality (P = .005). Among CTX-S patients who were adequately treated, initial use of unnecessarily broad antibiotics was associated with increased in-hospital mortality (P = .003). Ceftriaxone resistance was common in this cohort of culture positive COBP patients. Inappropriate coverage on day of admission was associated with greater likelihood of in-hospital mortality.
format Online
Article
Text
id pubmed-9276381
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-92763812022-07-13 Ceftriaxone resistance and adequacy of initial antibiotic therapy in community onset bacterial pneumonia Van Besien, Richard F. Hampton, Nicholas Micek, Scott T. Kollef, Marin H. Medicine (Baltimore) 3900 Much remains unknown about the impact of initial antibiotic adequacy on mortality in community onset bacterial pneumonia (COBP). Therefore, we performed a study to determine how the adequacy of initial antibiotic therapy affects in-hospital mortality for patients with COBP. We carried out a retrospective cohort study among the 11 BJC Healthcare community and academic hospitals in Missouri and Illinois. The electronic medical records for BJC Healthcare were queried to obtain a set of patient admissions with culture positive (respiratory or blood) COBP admitted from January 1, 2016 through December 31, 2019. Patients with COBP required an International Classification of Diseases (ICD)-10 diagnostic code for pneumonia, admission to the hospital through an emergency department, a chest radiograph with an infiltrate, an abnormal white blood cell count or temperature, an order for 1 or more new antibiotics, and a positive respiratory or blood culture. Antibiotic selection was deemed adequate if the patient had organisms susceptible to at least one of the antibiotics received according to in vitro testing using standard laboratory breakpoints. Among 36,645 screened pneumonia admissions, 1843 met criteria for culture positive COBP. Eight hundred nineteen (44.4%) had ceftriaxone-resistant (CTX-R) organisms and 1024 had ceftriaxone-sensitive (CTX-S) organisms. The most common CTX-R pathogens were methicillin resistant Staphylococcus aureus (46.9%), Pseudomonas species (38.4%), and Escherichia coli (4.5%). On the day of admission 71% of all patients were given adequate antibiotic treatment (62.2% of CTX-R and 77.9% of CTX-S). Unnecessarily broad initial treatment was administered to 57.1% of CTX-S patients. In a logistic regression model accounting for comorbidities and severity of illness, inadequate therapy on the day of admission was associated with higher in-hospital mortality (P = .005). Among CTX-S patients who were adequately treated, initial use of unnecessarily broad antibiotics was associated with increased in-hospital mortality (P = .003). Ceftriaxone resistance was common in this cohort of culture positive COBP patients. Inappropriate coverage on day of admission was associated with greater likelihood of in-hospital mortality. Lippincott Williams & Wilkins 2022-05-27 /pmc/articles/PMC9276381/ /pubmed/35608417 http://dx.doi.org/10.1097/MD.0000000000029159 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0 (https://creativecommons.org/licenses/by-nc/4.0/)
spellingShingle 3900
Van Besien, Richard F.
Hampton, Nicholas
Micek, Scott T.
Kollef, Marin H.
Ceftriaxone resistance and adequacy of initial antibiotic therapy in community onset bacterial pneumonia
title Ceftriaxone resistance and adequacy of initial antibiotic therapy in community onset bacterial pneumonia
title_full Ceftriaxone resistance and adequacy of initial antibiotic therapy in community onset bacterial pneumonia
title_fullStr Ceftriaxone resistance and adequacy of initial antibiotic therapy in community onset bacterial pneumonia
title_full_unstemmed Ceftriaxone resistance and adequacy of initial antibiotic therapy in community onset bacterial pneumonia
title_short Ceftriaxone resistance and adequacy of initial antibiotic therapy in community onset bacterial pneumonia
title_sort ceftriaxone resistance and adequacy of initial antibiotic therapy in community onset bacterial pneumonia
topic 3900
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9276381/
https://www.ncbi.nlm.nih.gov/pubmed/35608417
http://dx.doi.org/10.1097/MD.0000000000029159
work_keys_str_mv AT vanbesienrichardf ceftriaxoneresistanceandadequacyofinitialantibiotictherapyincommunityonsetbacterialpneumonia
AT hamptonnicholas ceftriaxoneresistanceandadequacyofinitialantibiotictherapyincommunityonsetbacterialpneumonia
AT micekscottt ceftriaxoneresistanceandadequacyofinitialantibiotictherapyincommunityonsetbacterialpneumonia
AT kollefmarinh ceftriaxoneresistanceandadequacyofinitialantibiotictherapyincommunityonsetbacterialpneumonia